NEW YORK (GenomeWeb) – Biodesix today announced that its VeriStrat test has received a positive coverage decision from CareFirst Blue Cross Blue Shield.

VeriStrat is a blood-based proteomic test that helps guide treatment decisions for patients with non-small cell lung cancer.

CareFirst announced its position to extend coverage for the VeriStrat test in March and published a positive coverage policy earlier this week on its website, Biodesix said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.